New Photosensitizers for Photodynamic Therapy in Gastroenterology
Most applications of photodynamic therapy (PDT) in gastroenterology to date have used porfimer sodium as the photosensitizing agent. For destroying small lesions in the wall of the gastrointestinal tract in inoperable patients, it has proved to be most effective, but attempts to achieve circumferent...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1999-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/1999/454789 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550000560701440 |
|---|---|
| author | SG Bown AZ Rogowska |
| author_facet | SG Bown AZ Rogowska |
| author_sort | SG Bown |
| collection | DOAJ |
| description | Most applications of photodynamic therapy (PDT) in gastroenterology to date have used porfimer sodium as the photosensitizing agent. For destroying small lesions in the wall of the gastrointestinal tract in inoperable patients, it has proved to be most effective, but attempts to achieve circumferential mucosal ablation, as in the treatment of Barrett’s esophagus, have led to a high incidence of strictures, and all patients have cutaneous photosensitivity, which can last up to three months. Two new photosensitizers are of particular interest to gastroenterologists. PDT with metatetrahydroxyphenyl chlorin produces a similar biological effect as PDT with porfimer sodium, but the light doses required are much smaller, and cutaneous photosensitivity lasts only two to three weeks. Further, it can be used with percutaneous light delivery to destroy localized pancreatic cancers. The photosensitizing agent 5-amino levulinic acid, converted in vivo into the photoactive derivative protoporphyrin IX, sensitizes the mucosa much more than the underlying layers. This makes it feasible to destroy areas of abnormal mucosa without damaging the underlying muscle and is, therefore, better for treating Barrett’s esophagus. Detailed clinical studies are required to establish the real role of PDT with the use of these and other new photosensitizers. |
| format | Article |
| id | doaj-art-6250d8e0f6cf4a7e882037ad203d9d6f |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 1999-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-6250d8e0f6cf4a7e882037ad203d9d6f2025-02-03T06:07:52ZengWileyCanadian Journal of Gastroenterology0835-79001999-01-0113538939210.1155/1999/454789New Photosensitizers for Photodynamic Therapy in GastroenterologySG Bown0AZ Rogowska1National Medical Laser Centre, Institute of Surgical Studies, Royal Free and University College Medical School, London, UKNational Medical Laser Centre, Institute of Surgical Studies, Royal Free and University College Medical School, London, UKMost applications of photodynamic therapy (PDT) in gastroenterology to date have used porfimer sodium as the photosensitizing agent. For destroying small lesions in the wall of the gastrointestinal tract in inoperable patients, it has proved to be most effective, but attempts to achieve circumferential mucosal ablation, as in the treatment of Barrett’s esophagus, have led to a high incidence of strictures, and all patients have cutaneous photosensitivity, which can last up to three months. Two new photosensitizers are of particular interest to gastroenterologists. PDT with metatetrahydroxyphenyl chlorin produces a similar biological effect as PDT with porfimer sodium, but the light doses required are much smaller, and cutaneous photosensitivity lasts only two to three weeks. Further, it can be used with percutaneous light delivery to destroy localized pancreatic cancers. The photosensitizing agent 5-amino levulinic acid, converted in vivo into the photoactive derivative protoporphyrin IX, sensitizes the mucosa much more than the underlying layers. This makes it feasible to destroy areas of abnormal mucosa without damaging the underlying muscle and is, therefore, better for treating Barrett’s esophagus. Detailed clinical studies are required to establish the real role of PDT with the use of these and other new photosensitizers.http://dx.doi.org/10.1155/1999/454789 |
| spellingShingle | SG Bown AZ Rogowska New Photosensitizers for Photodynamic Therapy in Gastroenterology Canadian Journal of Gastroenterology |
| title | New Photosensitizers for Photodynamic Therapy in Gastroenterology |
| title_full | New Photosensitizers for Photodynamic Therapy in Gastroenterology |
| title_fullStr | New Photosensitizers for Photodynamic Therapy in Gastroenterology |
| title_full_unstemmed | New Photosensitizers for Photodynamic Therapy in Gastroenterology |
| title_short | New Photosensitizers for Photodynamic Therapy in Gastroenterology |
| title_sort | new photosensitizers for photodynamic therapy in gastroenterology |
| url | http://dx.doi.org/10.1155/1999/454789 |
| work_keys_str_mv | AT sgbown newphotosensitizersforphotodynamictherapyingastroenterology AT azrogowska newphotosensitizersforphotodynamictherapyingastroenterology |